Investigation of the -1377 polymorphism on the Apo-1/FAS promoter in systemic lupus erythematosus patients using allele-specific amplification

Pathology

Volumn 32, Issue 2, 2000, Pages 126-130

  Huang, Qi Rong ^a   Manolios, Nicholas ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Allele specific amplification; Apo 1 Fas gene; Polymorphism; Promoter; Systemic lupus erythematosus

Indexed keywords

ADENINE; DNA; FAS ANTIGEN; FAS LIGAND; GUANINE;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA FLANKING REGION; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MUTANT; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0034014893     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/003130200104376     Document Type: Article

References (17)

1. 1. Hetts SW. To die or not to die: an overview of apoptosis and its role in disease. J Am Med Assoc 1998; 279: 300-7.
2. 2. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56.
3. 3. Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429-40.
4. 4. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-29.
5. 5. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-9.
6. 6. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997; 34: 577-82.
7. 7. Sheffield VC, Beck JS, Kwitek AE, et al. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 1993; 16: 325-32.
8. 8. Inamdar A, Sintasath DM, Husted L, et al. Typing the HLA-B locus by a nested primer approach and oligonucleotide hybridization. Tissue Antigens 1996; 47: 519-29.
9. 9. Haliassons A, Chomel JC, Grandojouan S, et al. Detection of minority point mutations by modified PCR-technique: a new approach to a sensitive diagnosis of tumor-progression markers. Nucleic Acids Res 1994; 54: 3853-6.
10. 10. Sarkar G, Cassady J, Bottema CD, Sommer SS. Characterization of polymerase chain reaction amplification of specific alleles. Anal Biochem 1990; 186: 64-8.
11. 11. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
12. 12. Rudert F, Visser E, Forbes L, et al. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. DNA Cell Biol 1995; 14: 931-7.
13. 13. Ohsako S, Hara M, Harigai M, et al. Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 1994; 73: 109-14.
14. 14. Mysler E, Bini P, Drappa J, et al. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994; 93: 1029-34.
15. 15. Amasaki Y, Kobayashi S, Takeda T, et al. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin Exp Immunol 1995; 99: 245-50.
16. 16. Briggs MR, Kadonaga JT, Bell SP, Tijian R. Purification and biomedical characterization of the promoter specific transcription factor, SP-1. Science 1986; 234: 47-52.
17. 17. Ngo VM, Laverriere JN, Gourdji D. CpG methylation represses the activity of the rat prolactin in rat GH3 pituitary cell lines. Mol Cell Endocrinol 1995; 108: 95-105.